FORT LAUDERDALE, Fla., Nov. 13 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced that the Company's exclusive distributor in Italy, CTLM Italia, exhibited CTLM system results from universities in Italy and other international sites at the 4th Attualita in Senologia in Florence, Italy, October 29th-31st.
IMDS expects Italy to be one of its major European markets following early interest in the CT Laser Mammography (CTLM(R)) adjunctive solution to breast cancer detection. IMDS has several clinical research programs underway in Italy.
The meeting, which emphasized a multidisciplinary approach to managing breast cancer cases, featured scientific courses, symposia, and presentations, along with the technical exhibition. Sponsors included: Scuola Italiana di Senologia; Societa Italiana di Senologia; Gruppo Italiano Screening Mammografico; Societa Italiana di Radiologia Medica; Forza Operativa Nazionale sul Carcinoma Mammario; Europa Donna - Forum Italiano O.N.L.U.S.; and the European School of Oncology. Approximately 1400 physicians attended.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: http://www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2007 PR Newswire.
All rights reserved